Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Obesity linked to subsequent neoplasms in childhood cancer survivors

2.

Cancer patients with HIV have demonstrated safety with immune checkpoint inhibitors.

3.

For the first time in humans, a chemotherapy drug reaches the brain.

4.

Study: For predicting breast cancer, AI performs better than traditional risk models.

5.

Resection for Early Liver Cancer Tied to Improved Survival.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot